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Haemolytic Uraemic Syndrome (HUS) is an acquired disorder affecting mainly infants and children. The triad of this clinical syndrome is defined by: 1) Thrombotic or Microangiopathic Haemolytic Anaemia with schistocytes 2) Thrombocytopenia and 3) Acute Renal Failure (ARF) which can develop into Chronic Kidney Disease (CKD). The aim of this article is to provide an editorial/ commentary on the Clinical Medicine versus Clinical Anatomy of HUS.
HUS is the most common cause of Acute Renal Failure (ARF) in children with an equal sex incidence [1] . The annual incidence of VTEC infection varies geographically; it can range from 1 to 30 cases per 100,000 in industrialized countries. It is a rare syndrome post-puberty but it is also closely related to Thrombotic Thrombocytopenia (TTP) which is common in adults. The annual incidence of the Verocytotoxin-producing Esherichia Coli (VTEC) infection varies geographically from year to year, ranging from 1-30 cases per 100,000 in industrialized countries and is associated with HUS. HUS occurs in sporadic cases epidemics; between 1st January [2] and 31 st December [2] in England, a total of 3717 cases were reported with evidence of Shiga Toxin-Producing E. Coli (STEC) infection; sometimes following outbreaks. In Hamburg [3] , there was an outbreak with more than 900 cases. The disease has seasonal variation, being more common in the warmer months in children.
Renal histopathology is characterized by abnormal morphology applicable to afferent arterioles and glomeruli. The glomeruli show evidence of global sclerosis and glomerular thrombotic microangiopathy endothelial cell swelling; capillary wall thickening and glomerular basement membranes also evident. Interstitial fibro edematous change and tubular atrophy are marked. Arterial, arteriolar and capillary lumina are narrow with obstruction and intimal thickening. The nature of vascular involvement in the kidneys supports the hypothesis that HUS is mediated by systemic toxemia and endothelial cells are the primary target cells owing to action of Verocytotoxin. Histopathological findings provide clues not only to the diagnosis but also in the support of prognosis. Diffuse tubular interstitial change and global sclerosis indicate the degree of blood flow obstruction and prognosis. Renal blood flow obstruction caused by diffused arterial and arteriolar luminal stenosis may lead to irreversible changes in renal pathology Keywords: Haemolytic Uraemic Syndrome (HUS); Clinical medicine; Clinical anatomy; Chronic kidney disease; Acute renal failure; Haematology micro-organisms causing diarrhoea, (and those thus leading to HUS and/ or HUS related symptoms) may become more important in future health consultations [3] .
Introduction
Haemolytic Uraemic Syndrome (HUS) occurs due to Shigalike toxin activity via aberrant complement activation. HUS is typically classified into two primary types: 1) HUS due to infections, often associated with diarrohea (D+HUS, Shiga toxin-producing Escherichia Coli-HUS), with the rare exception of HUS due to a severe disseminated infection caused by Streptococcus; 2) HUS related to complement, such HUS is also known as "atypical HUS" and is not diarrohea associated (D-HUS, aHUS) [4] . Clinical features include proteinuria, renal impairment and history of E. coli diarrohea (hallmark of typical HUS). Encephalopathy is rare but can cause death. HUS is seen increasingly following outbreaks of infection with Verotoxin (VT)-producing organisms. It represents a growing public health problem and data suggest that more awareness of specific
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Between 1 st January [6] and 31 st December [6] in England, a total of 3717 cases were reported with evidence of Shiga Toxin-producing E. Coli (STEC) infection, and the crude incidence of STEC infection was 1•80/100 000 person-years. Incidence was highest in children aged 1-4 years (7•63/100 000 person-years) [2] .
HUS diarrohea association
Most common cause of HUS and intrinsic ARF in paediatrics in the UK, France and USA industrialized countries is diarrhoea. There are no specific therapies to treat the diarrohea. Mortality is as high as 8.5 % and up to 30 % of survivors may develop further Glomerular Filtration Rate (GFR) impairment or albuminuria [6] .
Use of anti-motility drugs may increase the risk of developing HUS and it is a rare syndrome post-puberty [1] . Atypical HUS (aHUS) can be inherited or acquired and does not appear to vary by race, gender or geographic area. Data on the prevalence of aHUS is limited [7, 8] (Table 3) .
HUS and laboratory tests/ investigations
Haemolysis and red cell fragmentation are usually evident at presentation, although this rarely develops later in the disease even after platelet count improvement (Table 4 ). Coagulation studies are usually normal with mildly raised D-dimer titres in contrast to Disseminated Intravascular Coagulation (DIC) [9] . The Von-Willebrand Factor (VWF) levels are usually markedly raised during acute illness while analysis may/ may not show ultra-large multimers [10] . Poor prognostic features at presentation include a high neutrophil count [11] . Severe thrombocytopenia is uncommon but prolonged thrombocytopenia for more than 10 days is associated with long-term renal picture. Factor VIII levels do not correlate with clinical outcome [12] . Table 5 summarizes laboratory tests/ investigations according to Haematology specialty. Figure 1 depicts HUS red cell morphology under microscopy.
Prognosis and treatment
Treatment is by supportive measure, and the main treatments are either Haemodialysis (HD) or Peritoneal Dialysis (PD) because of the ARF. The prognosis is dependent upon the aetiology and renal function; there is a poor prognosis if patient requires HD or PD more than 7 days, but good prognosis is conceivable with total recovery of renal function with no arterial hypertension, and no proteinuria. Children with intra-cerebral involvement may be treated with plasma 
HUS -Haematology
Full Blood Count (FBC) highlights an anaemic picture on presentation Coagulation highlights APTT and PT are both normal -suggests sepsis rather than HUS/TTP
Platelet and fibrin micro-thrombi is evident within the renal microvasculature
Thrombocytopenia is universal at some point in the illness
Haematinics highlight there is variability in Iron titres
Direct Coombes Test is Negative
Plasma Haptoglobin levels is decreased owing to Red Blood Cell (RBC) breakdown/ degradation
Raised Fraction Degradation Products (FDPs)
There is a slightly elevated D-Dimer There may be microcytosis Red cell enzymes and osmotic fragility are normal Reticulocyte count is elevated exchange, but efficacy and long-term use is not advisable [13] [14] [15] .
Major neurological dysfunction occurs in a third of patients in atypical HUS and less than 10% in typical HUS; is associated with a poor prognosis [7] . There should be supportive information made available for the patient and parent or career/guardian. Eculizumab is a monoclonal antibody that binds to C5 to prevent the formation of C5a and the membrane attack complex [7, 8] . This treatment has become popular and can be helpful for patients who may have extra renal involvement such as that seen in typical HUS. Its efficacy and safety in the treatment of aHUS has been highlighted recently [7, 8] .
Management
Either HD or PD treatments is essential when renal function is altered. It is crucial to control hypertension, thus preventing any longer term complications (Figures 2 and 3 ). RBC transfusion in children is common owing to anaemia [13] [14] [15] . Fraction Frozen Plasma (FFP) has been administered in adults [8] .
Research perspectives
Haemoglobin (Hb) is the most direct indicator of clinical severity in haemolytic diseases. Its level may be close to normal values in mild forms (Hb >10 g/dL) or reduced in moderate (Hb 8-10 g/dL), severe (Hb 6-8 g/dL), and very severe (Hb 6 g/dL) forms (WHO 1989). In a differential diagnosis, an acute onset is more frequently observed in RBC enzymopathies involving the Pentose Phosphate (PP) shunt 
HUS -Key Morphological Features
Peripheral blood smear depicts striking red cell fragmentation 
